Journal
SEMINARS IN LIVER DISEASE
Volume 24, Issue 2, Pages 139-154Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-2004-828891
Keywords
bile marker; serum marker; cholangiocarcinoma; cholangiocarcinogenesis
Categories
Ask authors/readers for more resources
Surgery remains the only curative treatment option for cholangiocarcinoma (CC). Currently, both early identification of CC in affected individuals at high risk and accurate diagnosis of unexplained biliary strictures are problematic. However, growing insights into biochemical and molecular mechanisms underlying biliary carcinogenesis have suggested serum and bile markers for the diagnosis of CC. These tools include tumor antigens or products (e.g., carbohydrate antigen [CA] 19-9), cytokines (e.g., interleukin-6), metabolic products (e.g., lactate), proteases (e.g., trypsinogen-2), regulatory peptides (e.g., pancreatic polypeptide), and (epi-)genetic lesions (e.g., K-ras and p53 mutations, p16(INK4a) or p14(ARF) promoter hypermethylation). In this article we discuss these new potential tumor markers for the diagnosis of CC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available